Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study (ALADIN)
Effect of a Long-acting Somatostatin on Disease Progression in Nephropathy Due to Autosomal Dominant Polycystic Kidney Disease: a Long-term Three Year Follow up Study
Sponsor: Mario Negri Institute for Pharmacological Research
A PHASE3 clinical study on Autosomal Dominant Polycystic Kidney Disease (ADPKD), this trial is completed. The trial is conducted by Mario Negri Institute for Pharmacological Research and has accumulated 5 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Apr 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Mario Negri Institute for Pharmacological Research
For direct contact, visit the study record on ClinicalTrials.gov .